417 related articles for article (PubMed ID: 36139402)
1. Age-Related NAFLD: The Use of Probiotics as a Supportive Therapeutic Intervention.
Campagnoli LIM; Marchesi N; Vairetti M; Pascale A; Ferrigno A; Barbieri A
Cells; 2022 Sep; 11(18):. PubMed ID: 36139402
[TBL] [Abstract][Full Text] [Related]
2. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD.
Gupta M; Krishan P; Kaur A; Arora S; Trehanpati N; Singh TG; Bedi O
Inflamm Res; 2021 Jul; 70(7):765-776. PubMed ID: 34212214
[TBL] [Abstract][Full Text] [Related]
4. The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review.
Carpi RZ; Barbalho SM; Sloan KP; Laurindo LF; Gonzaga HF; Grippa PC; Zutin TLM; Girio RJS; Repetti CSF; Detregiachi CRP; Bueno PCS; Mazuqueli Pereira ESB; Goulart RA; Haber JFDS
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955942
[TBL] [Abstract][Full Text] [Related]
5. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
[TBL] [Abstract][Full Text] [Related]
6. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
[TBL] [Abstract][Full Text] [Related]
7. Prebiotics and Probiotics: Effects on Dyslipidemia and NAFLD/NASH and the Associated Mechanisms of Action.
Rodríguez-Pastén A; Fernández-Martínez E; Pérez-Hernández N; Soria-Jasso LE; Cariño-Cortés R
Curr Pharm Biotechnol; 2023; 24(5):633-646. PubMed ID: 35984030
[TBL] [Abstract][Full Text] [Related]
8. Prebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease.
Mijangos-Trejo A; Nuño-Lambarri N; Barbero-Becerra V; Uribe-Esquivel M; Vidal-Cevallos P; Chávez-Tapia N
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834367
[TBL] [Abstract][Full Text] [Related]
9. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis.
Delzenne NM; Knudsen C; Beaumont M; Rodriguez J; Neyrinck AM; Bindels LB
Proc Nutr Soc; 2019 Aug; 78(3):319-328. PubMed ID: 30628563
[TBL] [Abstract][Full Text] [Related]
10. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications.
Chen J; Vitetta L
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32717871
[TBL] [Abstract][Full Text] [Related]
11. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
12. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
13. Combination of Probiotics and
Wang W; Xu AL; Li ZC; Li Y; Xu SF; Sang HC; Zhi F
Diabetes Metab J; 2020 Apr; 44(2):336-348. PubMed ID: 31950772
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.
Ebrahimzadeh Leylabadlo H; Ghotaslou R; Samadi Kafil H; Feizabadi MM; Moaddab SY; Farajnia S; Sheykhsaran E; Sanaie S; Shanehbandi D; Bannazadeh Baghi H
Eur J Clin Microbiol Infect Dis; 2020 Apr; 39(4):613-627. PubMed ID: 31828683
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
16. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics.
Nagashimada M; Honda M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360773
[TBL] [Abstract][Full Text] [Related]
17. Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review.
Castillo V; Figueroa F; González-Pizarro K; Jopia P; Ibacache-Quiroga C
Foods; 2021 Jul; 10(8):. PubMed ID: 34441497
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Probiotics (MCP
Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
[TBL] [Abstract][Full Text] [Related]
19. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
Miura K; Ohnishi H
World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
